All American to Field KarboLyn Clinical Study

BILLINGS, Mont.—All American Pharmaceutical & Natural Foods Corporation (AAP) announced its upcoming 2014 KarboLyn® clinical study. The study, “A Placebo-Controlled Double-Blind Pilot Study: Blood Sugar Response to KarboLyn® or a Glucose Drink during Aerobic Activity," will examine the impact this novel, proprietary homopolysaccharide mixture has on glucose response in normal and pre-diabetic adults during aerobic activity. The study will be headed by Thomas Harman, a former family medicine department chairman at the Mayo Clinic in Rochester, Minnesota.

“We already know KarboLyn® behaves somewhat differently than the standard ‘sugar solution’ when it is being consumed by normal adults before athletic workouts," said CEO Jeff Golini. “In addition to the glucose response in these normal people during aerobic activity, it may also have a unique impact on the pre-diabetics and hence other uses—that is also what this research is going to tell us." The study will be fielded this summer.

For more information on blood glucose levels, read the INSIDER article “Natural Ingredients Supporting Healthy Blood Sugar"